JP2009541225A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541225A5 JP2009541225A5 JP2009515681A JP2009515681A JP2009541225A5 JP 2009541225 A5 JP2009541225 A5 JP 2009541225A5 JP 2009515681 A JP2009515681 A JP 2009515681A JP 2009515681 A JP2009515681 A JP 2009515681A JP 2009541225 A5 JP2009541225 A5 JP 2009541225A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- independently
- cyclic
- saturated
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 37
- 229910052801 chlorine Inorganic materials 0.000 claims 32
- 229910052731 fluorine Inorganic materials 0.000 claims 32
- 229910052740 iodine Inorganic materials 0.000 claims 32
- 125000004122 cyclic group Chemical group 0.000 claims 30
- 229920006395 saturated elastomer Polymers 0.000 claims 29
- 229910052794 bromium Inorganic materials 0.000 claims 27
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 150000002118 epoxides Chemical class 0.000 claims 11
- 208000026278 immune system disease Diseases 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 7
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 6
- 101100516572 Caenorhabditis elegans nhr-8 gene Proteins 0.000 claims 6
- 101150065749 Churc1 gene Proteins 0.000 claims 6
- 102100038239 Protein Churchill Human genes 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 230000001613 neoplastic effect Effects 0.000 claims 5
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 claims 3
- 230000003394 haemopoietic effect Effects 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 125000003700 epoxy group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 230000003381 solubilizing effect Effects 0.000 claims 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 2
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000002202 Polyethylene glycol Chemical group 0.000 claims 1
- 150000001371 alpha-amino acids Chemical class 0.000 claims 1
- 235000008206 alpha-amino acids Nutrition 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000004712 monophosphates Chemical class 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229920000570 polyether Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Chemical group 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 239000001226 triphosphate Substances 0.000 claims 1
- 235000011178 triphosphate Nutrition 0.000 claims 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims 1
- OBTVWCKNWSCBOI-FNHSGVBUSA-N CCc1c([C@@](C)(CC2)C[C@]3(C)[C@@H]2C(C)(C)CCC3)c(C)cc(OC(C(CCCN)N)=O)c1 Chemical compound CCc1c([C@@](C)(CC2)C[C@]3(C)[C@@H]2C(C)(C)CCC3)c(C)cc(OC(C(CCCN)N)=O)c1 OBTVWCKNWSCBOI-FNHSGVBUSA-N 0.000 description 1
- HLGZRWSYDUMIOK-AODCHWHPSA-N CCc1c([C@](C)(CC2)C[C@]3(C)[C@@H]2C(C)(C)CCC3)c(C)cc(OC(C(CCCCN)N)=O)c1 Chemical compound CCc1c([C@](C)(CC2)C[C@]3(C)[C@@H]2C(C)(C)CCC3)c(C)cc(OC(C(CCCCN)N)=O)c1 HLGZRWSYDUMIOK-AODCHWHPSA-N 0.000 description 1
- 0 CCc1c([C@](C)(CC2)C[C@]3(C)[C@]2C(C)(C)CCC3)c(C)cc(OC(CSCCO*CCO*CCOC)=O)c1 Chemical compound CCc1c([C@](C)(CC2)C[C@]3(C)[C@]2C(C)(C)CCC3)c(C)cc(OC(CSCCO*CCO*CCOC)=O)c1 0.000 description 1
- FWXXZNHXWWXXPF-NYMWAARRSA-N C[C@@](CC1)([C@H](C2)[C@]3(C)[C@@H]1C(C)(C)CCC3)c(c(C)c1)c2cc1OC(CNC(CNC(C(CCCCN)N)=O)=O)=O Chemical compound C[C@@](CC1)([C@H](C2)[C@]3(C)[C@@H]1C(C)(C)CCC3)c(c(C)c1)c2cc1OC(CNC(CNC(C(CCCCN)N)=O)=O)=O FWXXZNHXWWXXPF-NYMWAARRSA-N 0.000 description 1
- KAIYCJXUCHUUBS-GKJHBJHPSA-K C[C@@](CC1)([C@H](C2)[C@]3(C)[C@@H]1C(C)(C)CCC3)c(c(C)c1)c2cc1OP([O-])(OP([O-])([O-])=O)=O Chemical compound C[C@@](CC1)([C@H](C2)[C@]3(C)[C@@H]1C(C)(C)CCC3)c(c(C)c1)c2cc1OP([O-])(OP([O-])([O-])=O)=O KAIYCJXUCHUUBS-GKJHBJHPSA-K 0.000 description 1
- SQXRDISOYGDVJB-JBOOERSTSA-N C[C@@](CC1)([C@H](Cc2c3)[C@]4(C)[C@@H]1C(C)(C)CCC4)c2c(C)cc3OC(CNC(CNC(C(CCCN)N)=O)=O)=O Chemical compound C[C@@](CC1)([C@H](Cc2c3)[C@]4(C)[C@@H]1C(C)(C)CCC4)c2c(C)cc3OC(CNC(CNC(C(CCCN)N)=O)=O)=O SQXRDISOYGDVJB-JBOOERSTSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81525806P | 2006-06-21 | 2006-06-21 | |
| PCT/CA2007/001106 WO2007147252A1 (en) | 2006-06-21 | 2007-06-21 | Ship 1 modulator prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009541225A JP2009541225A (ja) | 2009-11-26 |
| JP2009541225A5 true JP2009541225A5 (enExample) | 2010-07-29 |
Family
ID=38833031
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515680A Withdrawn JP2009541224A (ja) | 2006-06-21 | 2007-06-21 | Ｓｈｉｐ１モジュレーター化合物 |
| JP2009515681A Withdrawn JP2009541225A (ja) | 2006-06-21 | 2007-06-21 | Ｓｈｉｐ１モジュレータープロドラッグ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515680A Withdrawn JP2009541224A (ja) | 2006-06-21 | 2007-06-21 | Ｓｈｉｐ１モジュレーター化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20110263539A1 (enExample) |
| EP (2) | EP2035367A1 (enExample) |
| JP (2) | JP2009541224A (enExample) |
| AU (2) | AU2007262621A1 (enExample) |
| CA (2) | CA2656339A1 (enExample) |
| WO (2) | WO2007147251A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040266865A1 (en) * | 2001-10-17 | 2004-12-30 | Raymond Andersen | SHIP 1 modulators |
| WO2009120162A1 (ru) * | 2008-03-25 | 2009-10-01 | Zhukovskij Oleg Igorevich | Субстанция "ua' orion" |
| WO2011069118A1 (en) | 2009-12-04 | 2011-06-09 | Aquinox Pharmaceuticals Inc. | Ship1 modulators and methods related thereto |
| WO2012024682A1 (en) * | 2010-08-20 | 2012-02-23 | The University Of British Columbia | Ship1 modulators and related methods |
| DE102011082871A1 (de) * | 2011-09-16 | 2013-03-21 | Florian, Prof. Dr. Lang | Therapeutische und diagnostische Targets für Autoimmunität, inflammatorische Prozesse und/oder immuner Pathogenese und/oder von Erkrankungen, welche auf Autoimmunität, inflammatorische Prozessen und/oder immuner Pathogenese beruhen |
| WO2014110036A1 (en) | 2013-01-09 | 2014-07-17 | Aquinox Pharmaceuticals Inc. | Ship1 modulators and methods related thereto |
| CN108892637A (zh) | 2013-03-14 | 2018-11-27 | 阿奎诺克斯药物（加拿大）公司 | Ship1调节剂及与其相关的方法 |
| US10100056B2 (en) | 2013-03-14 | 2018-10-16 | Aquinox Pharmaceuticals (Canada) Inc. | SHIP1 modulators and methods related thereto |
| AU2016281658A1 (en) | 2015-06-26 | 2017-12-07 | Aquinox Pharmaceuticals (Canada) Inc. | Crystalline solid forms of the acetate salt of (1s,3s,4r)-4-((3as,4r,5s,7as)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1h-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol |
| US10053415B2 (en) | 2016-01-20 | 2018-08-21 | Aquinox Pharmaceuticals (Canada) Inc. | Synthesis of a substituted indene derivative |
| WO2018126040A1 (en) | 2016-12-28 | 2018-07-05 | Aquinox Pharmaceuticals (Canada) Inc. | Crystalline solid forms of (1s,3s,4r)-4-((3as,4r,5s,7as)-4- (aminomethyl)-7a-methyl-1-methyleneoctahydro-1h-inden-5-yl)-3- (hydroxymethyl)-4-methylcyclohexanol |
| EP4143202A4 (en) * | 2020-04-20 | 2024-04-24 | ZebraPeutics Inc. | METHODS OF TREATING SHIP1-MEDIATED DISEASES WITH PELOROL DERIVATIVES |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003033517A1 (en) * | 2001-10-17 | 2003-04-24 | The University Of British Columbia | Ship 1 modulators |
| DE60327936D1 (de) * | 2002-10-17 | 2009-07-23 | Univ British Columbia | Modulatoren von ship-1 |
-
2007
- 2007-06-21 CA CA002656339A patent/CA2656339A1/en not_active Abandoned
- 2007-06-21 US US12/305,456 patent/US20110263539A1/en not_active Abandoned
- 2007-06-21 EP EP07720021A patent/EP2035367A1/en not_active Withdrawn
- 2007-06-21 WO PCT/CA2007/001105 patent/WO2007147251A1/en not_active Ceased
- 2007-06-21 JP JP2009515680A patent/JP2009541224A/ja not_active Withdrawn
- 2007-06-21 AU AU2007262621A patent/AU2007262621A1/en not_active Abandoned
- 2007-06-21 EP EP07720020A patent/EP2035360A1/en not_active Withdrawn
- 2007-06-21 AU AU2007262622A patent/AU2007262622A1/en not_active Abandoned
- 2007-06-21 US US12/305,459 patent/US20100323990A1/en not_active Abandoned
- 2007-06-21 CA CA002656333A patent/CA2656333A1/en not_active Abandoned
- 2007-06-21 WO PCT/CA2007/001106 patent/WO2007147252A1/en not_active Ceased
- 2007-06-21 JP JP2009515681A patent/JP2009541225A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009541225A5 (enExample) | ||
| JP2006511490A5 (enExample) | ||
| JP2009541224A5 (enExample) | ||
| JP2019512478A5 (enExample) | ||
| JP2008533191A5 (enExample) | ||
| RU2011133900A (ru) | Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с | |
| JP2018519357A5 (enExample) | ||
| JP2018528261A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| JP2010530881A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| JP2010527913A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2014528466A5 (enExample) | ||
| JP2015518904A5 (enExample) | ||
| RU2010116274A (ru) | Аналоги азацитидина и их применение | |
| JP2010514768A5 (enExample) | ||
| JP2014532716A5 (enExample) | ||
| JP2013530179A5 (enExample) | ||
| JP2013544799A5 (enExample) | ||
| JP2010500962A5 (enExample) | ||
| JP2019500315A5 (enExample) | ||
| JP2011517697A5 (enExample) | ||
| JP2009539943A5 (enExample) | ||
| US11883423B2 (en) | Nucleobase analogue derivatives and their applications |